Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 1.00 |
| ▸ | RET | P07949 | 9/20 | 1.00 |
| ▸ | CDK1 | P06493 | 7/20 | 1.00 |
| ▸ | CDC7 | O00311 | 6/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 6/20 | 1.00 |
| ▸ | PRKACA | P17612 | 6/20 | 1.00 |
| ▸ | HIPK2 | Q9H2X6 | 6/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 1.00 |
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 5/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 5/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 2/20 | 1.00 |
| ▸ | PIM1 | P11309 | 4/20 | 0.71 |
| ▸ | JAK2 | O60674 | 3/20 | 0.71 |
| ▸ | FLT3 | P36888 | 3/20 | 0.71 |
| ▸ | JAK3 | P52333 | 3/20 | 0.71 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.71 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777007 | 0.83 | CDC7 (1.00) | CDK2RETCDK1CDC7MAP4K4 | |
| SCHEMBL1047198 | 0.83 | CDC7 (1.00) | CDK2RETCDK1CDC7MAP4K4 | |
| SCHEMBL3770553 | 0.81 | RET (1.00) | CDK2RETCDK1CDC7MAP4K4 | |
| SCHEMBL8939628 | 0.80 | CDK2 (0.69) | CDK2RETCDK1CDC7MAP4K4 | |
| SCHEMBL8939574 | 0.79 | CDC7 (0.66) | CDK2RETCDK1CDC7MAP4K4 | |
| SCHEMBL1668583 | 0.78 | CDK2 (0.80) | CDK2RETCDK1CDC7MAP4K4 | |
| SCHEMBL15172141 | 0.77 | CDK2 (0.68) | CDK2RETCDK1CDC7MAP4K4 | |
| SCHEMBL15172140 | 0.76 | CDK2 (0.70) | CDK2RETCDK1CDC7MAP4K4 | |
| SCHEMBL13239582 | 0.76 | CCNB2 (0.71) | CDK2RETCDK1CDC7MAP4K4 | |
| SCHEMBL3769935 | 0.75 | RET (1.00) | CDK2RETCDK1CDC7MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2786995-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2311837-B1 | Azaindoles useful as inhibitors of jak and other protein kinases | VERTEX PHARMA (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-7855205-B2 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-7855205-B2 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20060183900-A1 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-17 | — | — | US | disclosed |
| WO-2006050076-A1 | PYRIMIDINYL SUBSTITUTED FUSED-PYRROLYL COMPOUNDS USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | CDK2 23/4885RET 472/4885CDK1 45/4885 |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | CDK2 23/4885RET 472/4885CDK1 45/4885 |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | LCK, PDXK, CHUK | CDK2 154/4885RET 1280/4885CDK1 172/4885 |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | CDK2 23/4885RET 472/4885CDK1 45/4885 |
| US-20060183900-A1 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | TK1, MAP3K1, MAP3K2 | CDK2 7/4885RET 304/4885CDK1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.